
==== Front
Eur J Med Res
Eur J Med Res
European Journal of Medical Research
0949-2321
2047-783X
BioMed Central London

39227895
2043
10.1186/s40001-024-02043-8
Review
Chromosomal instability: a key driver in glioma pathogenesis and progression
http://orcid.org/0000-0002-0166-105X
Mazzoleni Adele 1
Awuah Wireko Andrew andyvans36@yahoo.com

2
http://orcid.org/0000-0003-0615-8397
Sanker Vivek 3
http://orcid.org/0000-0002-7979-2834
Bharadwaj Hareesha Rishab 4
http://orcid.org/0000-0003-0004-7389
Aderinto Nicholas 5
Tan Joecelyn Kirani 6
Huang Helen Ye Rim 7
Poornaselvan Jeisun 8
http://orcid.org/0000-0001-6782-730X
Shah Muhammad Hamza 9
Atallah Oday 10
Tawfik Aya 11
Elmanzalawi Mohamed Elsayed Abdelmeguid Elsayed 12
Ghozlan Sama Hesham 13
Abdul-Rahman Toufik 2
Moyondafoluwa Jeremiah Adepoju 14
http://orcid.org/0000-0002-2206-7236
Alexiou Athanasios 15161718
http://orcid.org/0000-0002-9020-874X
Papadakis Marios drmariospapadakis@gmail.com

19
1 https://ror.org/026zzn846 grid.4868.2 0000 0001 2171 1133 Barts and the London School of Medicine and Dentistry, London, UK
2 https://ror.org/01w60n236 grid.446019.e 0000 0001 0570 9340 Sumy State University, Sumy, Ukraine
3 grid.413226.0 0000 0004 1799 9930 Department Of Neurosurgery, Trivandrum Medical College, Trivandrum, India
4 https://ror.org/027m9bs27 grid.5379.8 0000 0001 2166 2407 Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK
5 https://ror.org/03bag5a72 grid.411274.5 0000 0001 0583 749X Internal Medicine Department, LAUTECH Teaching Hospital, Ogbomoso, Nigeria
6 https://ror.org/02wn5qz54 grid.11914.3c 0000 0001 0721 1626 Faculty of Medicine, University of St Andrews, St. Andrews, Scotland, UK
7 https://ror.org/01hxy9878 grid.4912.e 0000 0004 0488 7120 Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland
8 https://ror.org/05m7pjf47 grid.7886.1 0000 0001 0768 2743 School of Medicine, University College Dublin, Dublin, Ireland
9 https://ror.org/00hswnk62 grid.4777.3 0000 0004 0374 7521 School of Medicine, Queen’s University Belfast, Belfast, UK
10 https://ror.org/00f2yqf98 grid.10423.34 0000 0000 9529 9877 Department of Neurosurgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
11 https://ror.org/05y06tg49 grid.412319.c 0000 0004 1765 2101 Faculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, Egypt
12 https://ror.org/0516ah480 grid.275033.0 0000 0004 1763 208X Graduate University for Advanced Studies, SOKENDAI, Kanagawa, Japan
13 grid.442567.6 0000 0000 9015 5153 Arab Academy for Science, Technology & Maritime Transport, Alexandria, Egypt
14 Faculty of Clinical Sciences, Department of Medicine and Surgery, Ile-Ife, Osun State Nigeria
15 https://ror.org/05t4pvx35 grid.448792.4 0000 0004 4678 9721 University Centre for Research & Development, Chandigarh University, Chandigarh-Ludhiana Highway, Mohali, Punjab India
16 Funogen, Department of Research & Development, Athens, Greece
17 Department of Research & Development, AFNP Med, 1030 Vienna, Austria
18 Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, NSW 2770 Australia
19 https://ror.org/00yq55g44 grid.412581.b 0000 0000 9024 6397 Department of Surgery II, University Hospital Witten-Herdecke, University of Witten-Herdecke, Heusnerstrasse 40, 42283 Wuppertal, Germany
4 9 2024
4 9 2024
2024
29 4518 2 2024
26 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Chromosomal instability (CIN) is a pivotal factor in gliomas, contributing to their complexity, progression, and therapeutic challenges. CIN, characterized by frequent genomic alterations during mitosis, leads to genetic abnormalities and impacts cellular functions. This instability results from various factors, including replication errors and toxic compounds. While CIN’s role is well documented in cancers like ovarian cancer, its implications for gliomas are increasingly recognized. CIN influences glioma progression by affecting key oncological pathways, such as tumor suppressor genes (e.g., TP53), oncogenes (e.g., EGFR), and DNA repair mechanisms. It drives tumor evolution, promotes inflammatory signaling, and affects immune interactions, potentially leading to poor clinical outcomes and treatment resistance. This review examines CIN’s impact on gliomas through a narrative approach, analyzing data from PubMed/Medline, EMBASE, the Cochrane Library, and Scopus. It highlights CIN’s role across glioma subtypes, from adult glioblastomas and astrocytomas to pediatric oligodendrogliomas and astrocytomas. Key findings include CIN’s effect on tumor heterogeneity and its potential as a biomarker for early detection and monitoring. Emerging therapies targeting CIN, such as those modulating tumor mutation burden and DNA damage response pathways, show promise but face challenges. The review underscores the need for integrated therapeutic strategies and improved bioinformatics tools like CINdex to advance understanding and treatment of gliomas. Future research should focus on combining CIN-targeted therapies with immune modulation and personalized medicine to enhance patient outcomes.

Keywords

Chromosomal instability
Gliomas
Neuro-oncology
Molecular genetics
Private Universität Witten/Herdecke gGmbH (3128)Open Access funding enabled and organized by Projekt DEAL.

issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Chromosomal instability (CIN) is a significant biological phenomenon involved in the etiology of many illnesses, most notably cancer [1]. CIN is characterized by an increased frequency of genomic changes during mitotic processes, disrupting the genetic content distribution to progeny cells. This results in the accumulation of genetic abnormalities, which significantly impacts cellular performance. CIN has become a more widely recognized and essential determinant in carcinogenesis and disease progression in cancer genetics [2].

The consistency of chromosomal preservation and distribution during mitotic division is critical to cellular life and performance. Nonetheless, genomic integrity is constantly threatened by various harmful agents, including replication errors, exposure to toxic compounds, and endogenous reactive oxygen species [3]. Cellular systems have evolved reparative processes to repair DNA damage, bolstering genetic integrity. However, breaches in these protective regimes can result in CIN, which manifests in various genomic repercussions, including aneuploidy, chromosomal translocations, and genomic amplifications, all of which have carcinogenic implications.

CIN has been linked to several cancers, most notably ovarian cancer [4]. Emerging evidence, however, links CIN to brain malignancies, specifically gliomas, which are glial progenitor-derived neoplasms [5]. Elucidating the link between CIN and gliomas may provide unique molecular insights, leading to novel diagnostics and treatments. Despite advances in clinical therapy, gliomas continue to have poor prognosis due to their proliferative activity and resistance to traditional medicines.

Recent findings have highlighted the role of non-coding RNAs (ncRNAs) in modulating CIN, adding another layer of complexity to the regulation of genomic stability. DNA methylation-related long non-coding RNAs (DMlncRNAs) modulate gene expression by interacting with chromosomal modifications or remodeling factors, thereby affecting genomic instability and glioma progression. In lower grade gliomas (LGGs), specific DMlncRNAs have been identified as key regulators of genome instability and the tumor microenvironment (TME), impacting immune cell infiltration and patient prognosis [6]. This underscores the importance of epigenetic regulation in gliomagenesis and the potential for DMlncRNAs to serve as prognostic markers and therapeutic targets. This highlights the interplay between genetic and epigenetic mechanisms in gliomagenesis.

CIN-mediated changes commonly intersect critical oncological pathways, affecting key tumor suppressor genes, oncogenes, and DNA repair-centric genes such as TP53, PTEN, and EGFR [7–9]. The cumulative genomic landscape created by CIN gives neoplastic cells an adaptive advantage, allowing them to avoid canonical regulatory checkpoints and sustain uncontrolled proliferation [10]. In gliomas with pronounced CIN, the interplay between canonical and non-canonical DNA repair pathways becomes particularly evident. For example, homologous recombination deficiency (HRD), characterized by an impaired ability to repair double-stranded breaks through homologous recombination repair (HRR), can exacerbate genomic instability and tumor progression [11]. Tumors with HRD often exhibit heightened sensitivity to interstrand crosslink (ICL)-inducing therapies and poly(ADP-ribose) polymerase (PARP) inhibitors. Notably, traditional methods for assessing HRD, such as chromosomal microarray (CMA), may not capture the full spectrum of HRD signatures compared to advanced techniques like optical genome mapping (OGM), which can detect additional variants indicative of HRD [11]. This enhanced sensitivity underscores the need to explore both canonical and non-canonical repair mechanisms to fully understand how CIN drives glioma progression and influences treatment outcomes. Gliomas with significant CIN are associated with increased virulence, correlating with poorer clinical outcomes [10].

As CIN continuously modifies the genomic constitution of neoplastic cells, emergent sub-clonal entities have the potential to survive existing treatment options [12]. CIN, a hallmark of human cancer, results from errors in chromosome segregation during mitosis, leading to structural and numerical chromosomal abnormalities. This not only generates genomic heterogeneity that acts as a substrate for natural selection but also promotes inflammatory signaling by introducing double-stranded DNA into the cytosol, engaging the cGAS-STING anti-viral pathway [12]. These multipronged effects highlight CIN as a central driver of tumor evolution and underscore its role in the interaction between tumor cells and the microenvironment, influencing immune editing and evasion. Understanding the genetic complexities of gliomas and CIN’s influence on them, particularly in treatment-resistant glioma subtypes and their responses to currently available interventions, is crucial.

Recent discoveries of the interaction of CIN and gliomas can reshape oncological care, potentially opening the door to precision-oriented therapy options. Nonetheless, a complete understanding of CIN’s roles in gliomas and its interplays with further pathological mechanisms currently needs to be improved.

Methods

A narrative review was carried out to provide a comprehensive overview of CIN in all documented types of gliomas. Articles restricted to the English language were included from inception until August 2024. Pubmed/Medline, EMBASE, the Cochrane Library and Scopus databases were searched, including the terms “chromosomal instability” “glioma,” and their respective synonyms. To ensure the completeness of the review, the reference lists of included articles were manually searched for additional relevant studies. References cited in recent reviews on similar topics were also manually reviewed to identify additional sources that could contribute to the search strategy. Standalone abstracts, conference proceedings, case reports, and posters were excluded, with priority given to the inclusion of high-quality and reliable evidence. In addition, the review did not limit the number of studies to provide a comprehensive understanding. It included descriptive, animal model, cohort, and observational studies from both preclinical and clinical settings to provide a holistic perspective. Both the adult and pediatric populations were also included in order to ensure a comprehensive summary of all the currently available literature on the topic up to date. Table 1 summarizes the methodology.Table 1 Summary of methodology

Methodology steps	Description	
Literature search	PubMed/MEDLINE, EMBASE, Scopus and the Cochrane Library	
Inclusion criteria	Various study designs including experimental studies, randomized controlled trials, prospective and retrospective cohort studies

Studies involving both pediatric and adult populations

Studies providing raw data

Full-text articles published in English

	
Exclusion criteria	Non-English studies, stand-alone abstracts, conference proceedings, editorials, commentaries, and letters	
Search terms	Key words such as ‘chromosomal instability’, ‘CIN’, and ‘Gliomas’’ were used for a comprehensive database search	
Additional search	A manual search was performed to include references from recently published procedure-specific and disease-specific reviews	
Sample size requirement	No strict sample size requirement	

Genetic background of CIN and an overview of CIN in early glioma development and progression

CIN is a well-established form of genomic instability with enduring relevance in cancer research. Over a century ago, pioneering observations by Theodor Boveri [13] and David von Hansemann [14] unveiled the presence of structural and numerical chromosomal aberrations as defining characteristics of cancer. CIN originates from genetic mutations affecting genes responsible for maintaining chromosomal structure and governing mitotic processes. This disruptive mechanism yields substantial chromosomal damage, afflicting chromosome count and structural integrity [15, 16]. CIN leads to various outcomes, including segmental ane­uploidy, point mutations, CNAs, and structural modifications. The impact is so significant that it can result in the acquisition or loss of chromosomal se­gments or even e­ntire chromosomes within a single mitotic e­vent [17]. It is important to emphasize that although structural chromosomal modifications and aneuploidy can be indicative—hallmarks of CIN, they do not always represent the same underlying processes [18]. In specific clinical contexts and congenital conditions such as trisomy 21, aneuploidy can remain static or stable, decoupled from the dynamic CIN process, further highlighting the intricate spectrum of genomic instability [19–21]. CIN encapsulates the continuum of chromosomal alterations across successive cellular generations, portraying a multifaceted facet of cancer biology.

The emergence of micronuclei typically concomitant with CIN highlights a significant cellular consequence of this instability. During cell division, chromosomes that fail to integrate into a daughter nucleus give rise to micronuclei encapsulated within their distinct nuclear membranes [22]. In the context of gliomas, the primary cell line NCH149, characterized by elevated levels of numerical CIN, exhibits spontaneous micronucleus formation, albeit accompanied by a relatively modest degree of re CIN [23, 24]. Notably, passages of NCH149 cells manifested a substantial prevalence of micronuclei, reaching proportions of 33% and 71% respectively, underscoring the dynamic nature of this process [23, 24]. Moreover, the size of chromosomes exhibits a discernible correlation with the propensity to become sequestered within micronuclei [25]. Chromosomes featuring larger kinetochores have been demonstrated to be more prone to forming erroneous merotelic kinetochore–microtubule attachments, with reported error rates of 7.0% compared to 1.6% for chromosomes endowed with smaller kinetochores, as evidenced in studies involving Indian muntjac cells [26]. This phenomenon may be attributed to chromosomal lagging from kinetochore size discrepancies and potential cohesion fatigue. It is plausible that larger chromosomes are more susceptible to cohesion fatigue, thereby elevating the likelihood of merotelic attachments, further perpetuating the cycle of CIN in these cells.

Chromosomes that find themselves enclosed within micronuclei in cancer cells are susceptible to a catastrophic phenomenon known as chromothripsis. This intricate process has been documented in more than 500 cases cataloged in a meticulously curated chromothripsis database, which raises intriguing questions regarding the potential preferential damage to larger chromosomes by chromothripsis in specific tumor types and human malignancies as a whole [22, 27–29]. A wealth of studies has elucidated the pivotal role of centrosome amplification in fostering CIN within tumor cells [30–32]. Within animal cells, centrosomes occupy a central position in microtubule organization [33]. These centrosomes are instrumental in orchestrating the formation of bipolar mitotic spindles during mitosis, a requisite step for precisely segregating chromosomes [34]. The duplication of centrosomes is a highly regulated event, typically occurring at the onset of S-phase entry, ensuring that each daughter cell inherits a single centrosome during cytokinesis. Consequently, a cell may possess either one unduplicated centrosome or two duplicated centrosomes, with maintaining centrosome number homeostasis subject to stringent control mechanisms. Centrosome amplification, characterized by abnormal mitotic spindle formation and an elevated incidence of errors in chromosomal segregation, arises when this regulatory process becomes dysregulated [33, 34].

By directly influencing the DNA damage response (DDR) activity, including the DNA damage checkpoint and the DNA repair machinery, the genetic changes that characterize glioma genomes may also be responsible for the suboptimal treatment response of such tumor types. Cells activate the phosphoinositide 3-kinase (PI3KK)-related kinases ATM, ATR, and DNA-dependent protein kinase (DNA-PK) in response to DNA damage. Following on, these kinases phosphorylate numerous downstream substrates, including the effector kinases Chk1 and Chk2, leading to the initiation of cell-cycle checkpoints and apoptosis. Several other proteins known as checkpoint mediators or adaptors, such as 53BP1, BRCA1, and MDC1, are also necessary to activate DDR signaling. Recent research has suggested that the DDR functions as a checkpoint for tumor growth, requiring early malignant lesions to inactivate p53 or other DDR components to advance to more aggressive stages [35].

In glioblastoma patients, copy number loss of the genes encoding the ATM/Chk2 and ATR/Chk1 pathways frequently occurs, with heterozygous loss of CHEK2 being the most common occurrence. The RCAS/tv-a system, in conjunction with platelet-derived growth factor (PDGF)-induced glioma models, has served as a valuable platform for investigating critical DNA Damage Response (DDR) molecules in glioma development. This experimental approach has shed light on the pivotal roles of ATM, Chk2, and p53, demonstrating their indispensability in restraining glioma tumor progression in murine models. Notably, the loss of any of these genes accelerates tumor growth and imparts a more aggressive phenotype to the gliomas, thereby elevating the incidence of high-grade tumors. Furthermore, the absence of Chk2 in gliomas results in compromised cell cycle checkpoints and apoptotic responses. Intriguingly, this deficiency undermines the survival benefits typically conferred by ionizing radiation (IR) observed in control mice [36, 37].

Recent findings have highlighted the potential of variations within the telomere domain to instigate genetic diseases, foster genomic diversity, and promote cell immortalization [38]. Critical telomere shortening leads to telomere malfunction, followed by successive bridge-fusion-breakage cycles, and results in numerical chromosomal abnormalities [39, 40]. In cells with critical telomere dysfunction, dicentric chromosome formation, and genomic instability, there is an increased vulnerability to oncogenic transformation [41–43]. Such findings have been consistently replicated, showing that telomerase activity is frequently found in malignant cerebral tumors, including glioblastoma, and is linked to shorter telomeres [44, 45]. The findings suggest that telomerase activity and shorter telomeres could indicate human glioma malignancy.

A significant link between supernumerary centrosomes and cancer, particularly about aberrant chromosomal segregation, is well established [46]. This theory has spurred extensive investigations into the role of supernumerary centrosomes in various types of cancer. An early study employed electron microscopy to explore the presence of supernumerary centrosomes in gliomas [47]. The results revealed both the existence of some supernumerary centrioles and centriole clusters. This research laid the groundwork for further investigations into the role of centrosomes in gliomas. Indeed, subsequent studies have consistently observed the prevalence of supernumerary centrosomes in high-grade glioma samples, particularly within prominent nuclei [48, 49]. Centrosome-specific antibodies were used to identify supernumerary centrosomes, and these findings have aligned with similar observations made in other cancer types. These collective findings underline the significance of supernumerary centrosomes in cancer development and their potential impact on chromosomal segregation. Compared to normal tissue, gliomas showed indicators of mitotic dysregulation, such as supernumerary centrosomes. Numerous malignancies frequently have elevated quantities of mitotic regulatory proteins and changed levels of centrosome structural proteins; hence, therapies that target these protein classes may soon be developed [50–52]. The role of CIN in early glioma development is summarized in Fig. 1.Fig. 1 Role of chromosomal instability in the development of early glioma. DNA: Deoxyribonucleic acid

Chromosomal instability and gliomas subtypes

Adult gliomas

Glioblastoma—IDH wildtype

Glioblastoma is a highly aggressive brain tumor with a dismal prognosis [53]. The “IDH wildtype” subtype of glioblastoma stands out due to specific genetic and molecular characteristics and its particularly pronounced CIN [54]. The genomic profiling of glioblastoma tumors has revealed a significant occurrence of chromosomal aberrations, such as amplifications, deletions, and structural variations [55]. The IDH wildtype subtype, which comprises the majority of glioblastoma, lacks mutations in the isocitrate de­hydrogenase (IDH) gene [56]. These tumors exhibit heightened CIN and frequently display structural and numerical chromosomal abnormalities [56]. This instability is a hallmark of IDH wildtype glioblastoma and substantially influences their aggressive behavior and resistance to therapeutic interventions [54]. CIN within the context of glioblastoma has exhibited a propensity to generate genetically diverse subclones, profoundly influencing responses to therapeutic interventions and disease recurrence [57]. Furthermore, augmented CIN within tumor-initiating cells [TICs] has been established to significantly enhance their tumorigenic potential, establishing a direct connection between genomic instability and their intrinsic capacity [58]. In IDH wildtype glioblastoma, one of the pivotal genetic alterations closely associated with CIN is the TP53 mutation, which occurs with notable frequency [59]. TP53, functioning as a tumor suppressor gene, is commonly mutated within this glioblastoma subtype, impairing its conventional role in cell cycle regulation and DNA repair mechanisms [60]. Consequently, genetic mutations accumulate within the tumor cells. In addition, amplifying the epidermal growth factor receptor (EGFR) gene represents another pivotal genetic modification linked to CIN in IDH wildtype glioblastoma [61]. EGFR amplification stimulates uncontrolled signaling pathways within the tumor cells, facilitating their unbridled proliferation and contributing to the genetic tumultuousness characterizing these tumors [61]. Beyond TP53 and EGFR, IDH wildtype glioblastoma frequently exhibit a spectrum of additional genomic alterations, affecting genes such as PTEN, CDKN2A/B, and RB1 [62]. These supplementary genetic anomalies further intensify CIN within the tumor, thereby augmenting the genetic intricacy of these malignancies. Importantly, it is essential to recognize that CIN within IDH wildtype glioblastoma operates through intricate feedback loops, wherein genetic aberrations in one signaling pathway can precipitate dysregulation in others, thus perpetuating a self-reinforcing cycle of genomic instability [63]. The role of CIN in the progression of glioblastoma—IDH wildtype has been illustrated in Fig. 2.Fig. 2 Role of chromosomal aberrations in the progression of glioblastoma—IDH wildtype. glioblastoma multiforme, GBM; isocitrate dehydrogenase, IDH; epidermal growth factor receptor, EGFR; tumor protein p53, TP53; phosphatase and tensin homolog, PTEN; cyclin-dependent kinase inhibitor 2A, CDKN2A; retinoblastoma protein 1, RB1

Astrocytomas with IDH mutations

Astrocytomas demonstrate a diverse genetic landscape that significantly impacts their clinical behavior and outcomes [64]. Within this category of tumors, there is a distinct subgroup characterized by IDH gene mutations, which are associated with CIN [64]. Notably, IDH1 and IDH2 gene mutations serve as a hallmark genetic alteration in astrocytomas linked to CIN [65]. Consequently, the aggregation of these mutations disrupts normal cellular metabolism, resulting in the accumulation called 2-hydroxyglutarate (d-2-HG) [66]. The innate mechanism d-2-HG interferes with DNA methylation, which is indispensable for gene expression regulation and stability and promotes CIN [66, 67]. In parallel, astrocytomas carrying IDH mutations manifest impaired DNA repair mechanisms [68]. The compromised DNA repair apparatus exhibits reduced effectiveness in rectifying DNA damage, including breaks and mutations, resulting in the accrual of errors during DNA replication and repair procedures, thereby contributing to chromosomal instability [68]. Astrocytomas harboring IDH mutations frequently encounter telomere dysfunction, heightening the susceptibility of chromosomes to instability [69]. Telomere shortening and dysfunction can culminate in the fusion of chromosome ends, further amplifying the chaos of chromosomal instability. Additional genetic modifications impacting pivotal genes involved in cell cycle regulation, such as TP53 and ATRX, have been discerned [70]. The dysregulation of these genes exacerbates CIN by perturbing the proper processes of DNA replication and repair. The genetic dysregulation in astrocytomas with IDH mutation has been summarized in Fig. 3.Fig. 3 Role of genetic dysregulation in astrocytomas with IDH mutation. IDH 1,2: isocitrate dehydrogenase 1,2. DNA: deoxyribonucleic acid. SAM: S-adenosine methionine. ATRX: ATRX (alpha-thalassemia/mental retardation, X-linked). TP 53: transformation-related protein 53

IDH-mutant oligodendroglioma

CIN plays a crucial role in developing and progression of IDH-mutant oligodendrogliomas, unique brain tumors. These tumors are characterized by specific genetic changes involving IDH mutations [71]. As a result of these mutations, an oncome­tabolite called 2-hydroxyglutarate (2-HG) accumulates abnormally [71]. This metabolite disrupts various cellular processes, including DNA repair mechanisms, ultimately contributing significantly to chromosomal instability [72]. The buildup of 2-HG in cells with IDH mutations hinders DNA repair mechanisms such as homologous recombination and non-homologous end-joining. Consequently, it leads to the persistence of DNA lesions and further exacerbates chromosomal instability [72]. CIN in IDH-mutant oligodendrogliomas often leads to aneuploidy, which refers to the loss or gain of critical genetic mate­rial. This process drives the development of more aggressive tumor phenotypes [73]. In particular, specific genomic alterations, such as losses of chromosomes 1p and 19q, regularly occur in IDH-mutant oligodendrogliomas and are closely linked to chromosomal instability [74]. CIN in the pathogenesis of IDH-mutant oligodendroglioma has been summarized in Fig. 4.Fig. 4 Role of chromosomal instability (CIN) in the pathogenesis of IDH-mutant oligodendroglioma. DNA: deoxyribonucleic acid. IDH: isocitrate dehydrogenase

Pediatric gliomas

BRAF V660E mutant oligodendroglioma

CIN is central in deciphering the intricate pathophysiology of BRAF V660E mutant oligodendrogliomas, especially in adolescents and children [73, 75–77]. Recent investigations have unveiled a unique subset of tumors within this category, characterized by their IDH wildtype status, oligodendroglioma-like morphology, and BRAF p.V600E mutation [73, 75–77]. Genome-wide methylation of these tumors exhibits a distinctive pattern of CIN, marked by gains in whole chromosome 7 and losses in entire chromosome 10, setting them apart from conventional oligodendrogliomas [73]. CIN, characterized by heightened rates of chromosomal changes encompassing copy number alterations, aneuploidy, and structural variations, plays a pivotal role in developing and progressing these neoplasms [77]. The widespread copy number alterations observed in this subset of tumors, involving more than ten chromosomes, underscore the profound genetic instability that underlies their pathophysiology [73]. Such chromosomal instabilities have been shown to cause aberrant DNA repair mechanisms, impaired cell cycle regulation, and dysregulated signaling pathways, fostering the growth and survival of oligodendroglioma cells [73, 75–78].

Furthermore, the BRAF p.V600E mutation in these tumors is critical to their pathophysiology [78]. This mutation, coupled with the observed CIN patterns, underscores the intricate interplay between genetic alterations and CIN [75]. The coexistence of these molecular features not only differentiates these tumors from conventional oligodendrogliomas but also necessitates precise diagnostic tools to distinguish them from molecular glioblastoma [76]. Understanding the pathophysiology of BRAF V660E mutant oligodendrogliomas within the context of CIN and molecular genetics is paramount for informed clinical decision-making. It enables tailoring treatment strategies to the specific characteristics of these tumors, avoiding unnecessary aggressive interventions when a more indolent clinical course is anticipated [73, 75].

Desmoplastic infantile gangliogliomas and astrocytomas

Desmoplastic infantile gangliogliomas (DIGs) and desmoplastic infantile astrocytomas (DAGs) are interesting entities defined within the World Health Organization’s classification of central nervous system (CNS) neoplasms. Such neoplasms typically affect infants and young children, with a predilection for infants under 24 months of age [79, 80]. The characterizations of these tumors are their large size, nodular contrast enhancement, cellular pleomorphism, and undifferentiated small-cell components. Complete surgical resection typically results in an excellent prognosis [80, 81]. Histologically, DIGs and DAGs exhibit similar desmoplastic features: a dense stromal matrix containing fibroblastic and neuroepithelial elements. Neoplastic cells are noted to be confined to solid nodules and adjacent leptomeninges [80]. A deeper analysis of published literature reveals that attempts at analyzing the influence of CINs on DIGs and DAGs have shown inconsistent findings. Comparative genomic hybridization (CGH) and array-based genomic profiling have been used to assess CIN in DIGs and DAGs. According to different studies, these tumors can be attributed to varying chromosomal alterations and no well-defined set of recurrent abnormalities [79–85]. The reporting of chromosomal aberrations has also been inconsistent, with different studies reporting various gains and losses of chromosomal regions [80, 86]. While the precise role of CIN in the pathogenesis of DIG remains unclear, this could influence tumor behavior, including growth patterns and responses to treatment. Still, future studies exploring this is paramount to ascertain definite conclusions.

Pediatric astrocytoma

Astrocytomas, the most prevalent type of glial tumors in the pediatric population, have a significant link to CIN [87]. Understanding the implications of CIN is crucial for comprehending the development and progression of these tumors. While genetic abnormalities in specific subtypes like pilocytic astrocytomas have been extensively studied, there is still much to learn about CIN within the broader spectrum of pediatric astrocytomas [88]. Pediatric astrocytomas exhibit considerable genetic chaos with widespread chromosomal imbalances that significantly affect their functionality and biology. The consequences resulting from such are diverse. Morphological plasticity, reflected in their variable histological features, can be attributed to a more significant number of dosage variations in their genes. First, CIN contributes to tumor heterogeneity, leading to the coexistence of genetically distinct subpopulations of astrocytomas within a single tumor [88–91].

Despite the overall genetic complexity, specific subtypes of astrocytomas, such as PXA and SEGA, exhibit a consistent pattern of ge­nomic instability in their subtelomeric rearrangements. Their patterns suggest the presence of specific genomic hotspots that are prone to instability and may contain key driver genes involved in tumorigenesis. A study by Grau et al. (2009) highlights this finding [89]. In addition, CIN is often associated with increased tumor aggressiveness and a higher risk of recurrence. It can drive the progression from low-grade astrocytomas to more malignant forms by promoting the acquisition of genetic alterations seen in higher grade tumors. References [88–90] have all provided evidence supporting this correlation. Specific chromosomal alterations may make patients less re­sponsive to traditional treatments like radiotherapy or chemotherapy. This further limits the options for their treatment.

In addition, these alterations can activate oncogenic pathways, such as the commonly disrupted mitoge­n-activated protein kinase (MAPK) pathway in astrocytomas [88]. As a result, targeted therapies that target the specific altered pathways are emerging as promising treatment approaches. This highlights the importance of comprehensive identification and characterization of chromosomal alterations (Fig. 5).Fig. 5 Role of chromosomal instability in pediatric astrocytoma. ERK, extracellular signal regulated kinase; JNK, c-Jun N-terminal kinase; MEK, Mitogen-activated protein kinase kinase

Association between CIN and immune responses in gliomas

CIN in gliomas is associated with a range of immune effects, including the modulation of immune cell infiltration, antigen presentation, and immune evasion [6, 92]. For instance, CIN-induced genomic alterations can lead to the expression of neoantigens, which may enhance tumor visibility to the immune system [92]. However, the high level of genetic diversity and heterogeneity driven by CIN can also contribute to immune escape mechanisms, such as the upregulation of immune checkpoint proteins and the development of an immunosuppressive TME [10, 35].

In gliomas, CIN often leads to increased levels of tumor-infiltrating lymphocytes (TILs), including T cells and macrophages, which may have varying impacts on tumor progression and treatment responses [93]. For example, elevated levels of TILs have been linked to both positive and negative outcomes in glioma patients, depending on the specific immune cell types and their functional states [93]. CIN also affects antigen presentation by disrupting the major histocompatibility complex (MHC) pathways, potentially impairing the ability of immune cells to recognize and attack tumor cells [35, 36].

Comparatively, in ovarian cancer, CIN similarly influences immune responses by driving the formation of a complex tumor microenvironment with high immune cell infiltration and altered antigen presentation [94]. Ovarian tumors with high CIN often exhibit a heightened immune checkpoint expression, contributing to immune evasion and resistance to immune checkpoint inhibitors [94]. This contrast highlights how CIN can have both analogous and distinct effects on immune responses across different cancer types.

The interplay between CIN and immune responses underscores the need for integrated therapeutic strategies that combine CIN-targeted therapies with immune modulation. Understanding how CIN shapes the immune landscape in gliomas and other cancers can lead to more effective treatments that address both genomic instability and immune evasion, ultimately improving patient outcomes.

CINdex: a bioinformatics tool for estimating CIN in cancer from next-generation sequencing data

DNA copy number change is a critical structural variation in human genomes. CNA refers to changes in copy number resulting from tumor tissue, whereas copy number variations (CNVs) pertain to differences in the copy number of germline cells. Numerous events in the occurrence or severity of malignancies have been linked to the chromosome instability suggested by these CNAs in the DNA. Different technologies, such as genotyping arrays, microarray-based comparative genome hybridization (array CGH), or, more recently, high-resolution next-generation sequencing (NGS), can assess these variations in DNA copy number [95].

Patients’ segment data can be globally analyzed using the Bioconductor software CINdex. Any segmentation method can submit its segment information to the CINdex Bioconductor program. By providing a comprehensive perspective of genomic instability, it calculates a novel measure of genomic instability throughout a chromosome (known as Chromosome-CIN, Standard-CIN, or Regular-CIN) and across cytobands (known as Cytoband-CIN), providing a better resolution of genomic instability.

The CIN values are calculated at the chromosomal and cytoband levels of the CINdex package, standard sections across the whole human genome. This makes it possible to compare the values of chromosomal instability between different patient groups (control vs. case), a common use case in translational research. The software also enables further downstream systems biology studies by linking the differently altered cytobands or chromosomes to genes and pathways [96, 97]. The inception of CINdex is instrumental, serving as an invaluable resource in predicting patient survival outcomes and tailoring personalized treatment paradigms aligned with the distinct genomic attributes of their tumors [98]. The tool’s contribution is eminent in the enhanced comprehension of CIN in gliomas, illuminating the genetic intricacies of the disease and its repercussions on tumor heterogeneity, therapy responsiveness, and overall patient outcomes.

Limitations of current approaches for CIN evaluation

Evaluating CIN in gliomas is crucial for understanding tumor behavior, prognosis, and response to treatment. Several methodologies are employed to assess CIN, but they come with limitations. For example, comparative genomic hybridization (CGH) compares the DNA of tumor cells to normal cells, detecting gains and losses of chromosomal regions across the entire genome [79–85]. However, CGH has lower resolution and cannot detect balanced translocations or small mutations. In addition, next-generation sequencing (NGS), which involves sequencing the entire genome or exome to provide comprehensive data on mutations, copy number variations, and other genomic alterations [95], is associated with high costs, complex data analysis, and interpretation challenges. To overcome these limitations, future research should focus on developing cost-effective, high-resolution techniques with robust bioinformatics support. Integrating multiple methodologies may provide a more comprehensive assessment of CIN, enhancing the accuracy of diagnosis and the effectiveness of personalized treatment strategies.

CINdex, while valuable for estimating CIN from NGS data, has several limitations. Its reliance on high-resolution segment data [95], which may be prone to inaccuracies or noise, can impact the precision of CIN measurements. The tool primarily measures CIN at chromosomal and cytoband levels [95], potentially missing finer-scale variations. In addition, CINdex’s performance depends on the quality of input data and segmentation methods, which can lead to inconsistencies across studies. Moreover, CINdex does not directly assess the functional consequences of CIN on tumor biology or treatment response, necessitating integration with other analytical methods to fully understand its clinical implications.

CIN and therapeutic implications

Gliomas present significant challenges regarding prognosis and treatment [99]. Among the hallmarks of gliomas is CIN, a critical factor in their progression [99]. While traditional treatments such as surgery, radiation, and chemotherapy remain foundational, their limitations have spurred interest in innovative therapies specifically targeting CIN [100]. Emerging therapies aim to address the broad spectrum of genetic and molecular aberrations linked to CIN, rather than focusing solely on specific mutations [101].

Targeted therapies have begun to explore the broader implications of CIN. For example, therapies that modulate the tumor mutation burden (TMB), which is often elevated in CIN-driven tumors, could enhance treatment efficacy. Elevated TMB can lead to increased neoantigen presentation, potentially making tumors more susceptible to immune checkpoint inhibitors. Agents such as nivolumab and pembrolizumab, which target immune checkpoints, show promise in this context, though response rates vary among patients [102]. In addition, CAR-T cell therapy, while still experimental for gliomas, could be tailored to target the diverse neoantigens resulting from CIN [103].

Moreover, targeted inhibition of pathways frequently disrupted by CIN, such as the PI3K/AKT/mTOR pathway, offers another strategy. Inhibitors like temsirolimus, which disrupt this signaling cascade, may mitigate tumor growth by countering the downstream effects of CIN [104]. Gene editing technologies like CRISPR/Cas9 also present potential, allowing precise alterations of genes affected by CIN to correct or disrupt their function [105]. However, these approaches face challenges, including the development of resistance, the genetic and phenotypic diversity of gliomas, and the need for personalized treatment strategies.

To effectively target CIN, future research must focus on integrating these approaches, considering how CIN impacts tumor mutation burden and immune response. This broader focus will enhance our ability to exploit CIN for therapeutic benefit, ultimately improving treatment outcomes for glioma patients [103].

Discussions and prospects

The exploration of CIN in gliomas is paving the way for transformative future perspectives that have the potential to revolutionize our understanding and management of these aggressive brain tumors. Several interconnected areas of research and innovation are poised to shape the landscape of glioma studies.

One prominent avenue is the ongoing investigation into the genomic landscape of gliomas, primarily influenced by CIN. As research advances, we anticipate identifying novel therapeutic targets intricately linked with CIN patterns [106]. This discovery promises to usher in an era of personalized treatments tailored to address the unique genetic anomalies in each patient’s tumor. Such precision medicine approaches hold the promise of significantly enhancing treatment outcomes. Emerging therapeutic strategies are increasingly focusing on CIN-specific vulnerabilities. For instance, agents that modulate microtubules, which play a crucial role in cell division and are affected by CIN, are being explored. In addition, targeting the DNA damage response pathways that are often dysfunctional in tumors with high levels of CIN could provide another therapeutic avenue. In colorectal carcinoma research, high CIN cases have shown that specific chromosomal aberrations, such as the loss of 17p, can occur earlier in cytogenetic evolution, influencing tumor behavior and metastasis [106]. Applying this knowledge to gliomas, identifying similar early and late chromosomal events could guide the development of combination therapies.

The issue of intratumoral heterogeneity, a direct result of CIN, necessitates a shift toward combination therapies as a standard practice in glioma treatment [107]. These multifaceted treatment regimens may encompass agents modulating CIN, like those affecting microtubules, alongside targeted drugs aimed at specific genetic alterations. Success in this realm hinges on our ability to decipher the complex interactions between different genetic subclones coexisting within these tumors.

Another intriguing prospect lies in harnessing CIN as a potential biomarker for early glioma detection and monitoring [108]. In the years to come, refined techniques may enable us to assess CIN within tumor tissue and in easily accessible tissues like peripheral blood lymphocytes. The potential could revolutionize early disease detection and risk assessment, fundamentally altering our approach to intervening in the nascent stages of glioma development. Understanding how CIN contributes to tumor heterogeneity and evolution is crucial. Recent large-scale, high-throughput sequencing studies have highlighted significant genetic diversity within individual tumors [109]. This diversity consists of various subpopulations or subclones that differ spatially and temporally. CIN plays a key role in driving this clonal diversification, working alongside other genetic mechanisms to create the complex genomic instability often observed in cancer. Cancer cells adeptly adjust chromosome missegregation rates to manage the acquisition of genetic diversity while maintaining beneficial genotypes, a strategy that could potentially be leveraged for therapeutic purposes [109]. For instance, whole-genome doubling events can accelerate clonal evolution in certain tumors, leading to favorable near-triploid karyotypes. This suggests that CIN-driven clonal speciation might bypass the reliance on initial truncal mutations [109]. Thus, unraveling the mechanisms governing the transition from advantageous to detrimental effects of CIN on tumor growth represents an intriguing research frontier. A deeper understanding of the precise point at which heightened genomic instability becomes detrimental could open novel avenues for intervention, allowing for controlled induction of CIN in a therapeutic context.

Furthermore, integrating data from diverse omics disciplines, spanning genomics, transcriptomics, and epigenomics, will provide a comprehensive understanding of the intricate relationships underpinning CIN, genetic alterations, and treatment responses. Advanced computational methodologies will play a pivotal role in deciphering the complex molecular interplay within gliomas. The transition from preclinical research to clinical trials is imminent. Robust clinical validation of therapies designed to modulate CIN and rigorous patient stratification based on CIN levels will be pivotal in evaluating safety and efficacy. Ultimately, future perspectives in glioma research will converge on patient-centered approaches. The vision of understanding each patient’s tumor’s unique genomic signature and tailoring treatment plans is rapidly gaining momentum. This paradigm shift toward personalized medicine holds the potential to improve overall patient outcomes significantly.

In summary, the study of CIN in gliomas heralds a new era of precision medicine and innovative therapeutic strategies. While challenges persist, the ongoing synergy between research and technological advancements is poised to shape the future of glioma diagnosis and treatment.

Conclusion

The study of CIN in gliomas gives crucial information about these complex brain tumors’ origin, progression, and therapy. CIN, characterized by structural and numerical chromosomal irregularities, contributes significantly to the stunning heterogeneity seen in gliomas in both adult and pediatric populations, forming unique genetic profiles within glioma subtypes. CIN’s developing function as a significant biomarker for early detection, risk assessment, and continuous disease monitoring represents an exciting path for investigation. Precision medicine techniques have the potential to revolutionize glioma therapy by tailoring treatments to the precise genomic aberrations caused by CIN, providing hope for better patient outcomes. The study of CIN in gliomas improves our understanding of the genomic intricacies inherent in these tumors and reveals novel therapeutic methods. As we enter the era of precision medicine, the future promises the promise of improved diagnostics, focused therapies, and, ultimately, a better prognosis for those with gliomas.

Acknowledgements

We acknowledge Icormed Research Collaborative for their research facilitation.

Disclosures

The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.

Author contributions

The study was conceptualized by AM and WAA. Material preparation, data collection, and analysis were performed by all authors. The first and final draft of the manuscript was written by all authors. All authors read and approved the final manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. The Open Access Publication of this article has been enabled by the German Projekt DEAL.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Adele Mazzoleni and Wireko Andrew Awuah have contributed equally and are the co-first authors.
==== Refs
References

1. He Z Wilson A Rich F Kenwright D Stevens A Low YS Thunders M Chromosomal instability and its effect on cell lines Cancer Rep 2023 6 6 e1822 10.1002/cnr2.1822
He Z, Wilson A, Rich F, Kenwright D, Stevens A, Low YS, Thunders M. Chromosomal instability and its effect on cell lines. Cancer Rep. 2023;6(6):e1822. 10.1002/cnr2.1822.10.1002/cnr2.1822
2. Drews RM Hernando B Tarabichi M Haase K Lesluyes T Smith PS Morrill Gavarró L Couturier DL Liu L Schneider M Brenton JD Van Loo P Macintyre G Markowetz F A pan-cancer compendium of chromosomal instability Nature 2022 606 7916 976 983 10.1038/s41586-022-04789-9 35705807
Drews RM, Hernando B, Tarabichi M, Haase K, Lesluyes T, Smith PS, Morrill Gavarró L, Couturier DL, Liu L, Schneider M, Brenton JD, Van Loo P, Macintyre G, Markowetz F. A pan-cancer compendium of chromosomal instability. Nature. 2022;606(7916):976–83. 10.1038/s41586-022-04789-9.35705807 10.1038/s41586-022-04789-9
3. Langie SA Koppen G Desaulniers D Al-Mulla F Al-Temaimi R Amedei A Azqueta A Bisson WH Brown DG Brunborg G Charles AK Chen T Colacci A Darroudi F Forte S Gonzalez L Hamid RA Knudsen LE Leyns L de Cerain L Salsamendi A Collins AR Causes of genome instability: the effect of low dose chemical exposures in modern society Carcinogenesis 2015 36 Suppl1 S61 S88 10.1093/carcin/bgv031 26106144
Langie SA, Koppen G, Desaulniers D, Al-Mulla F, Al-Temaimi R, Amedei A, Azqueta A, Bisson WH, Brown DG, Brunborg G, Charles AK, Chen T, Colacci A, Darroudi F, Forte S, Gonzalez L, Hamid RA, Knudsen LE, Leyns L, de Cerain L, Salsamendi A, Collins AR. Causes of genome instability: the effect of low dose chemical exposures in modern society. Carcinogenesis. 2015;36(Suppl1):S61–88. 10.1093/carcin/bgv031.26106144 10.1093/carcin/bgv031
4. Vias M Morrill Gavarró L Sauer CM Sanders DA Piskorz AM Couturier DL Ballereau S Hernando B Schneider MP Hall J Correia-Martins F Markowetz F Macintyre G Brenton JD High-grade serous ovarian carcinoma organoids as models of chromosomal instability Elife 2023 11 12 e83867 10.7554/eLife.83867
Vias M, Morrill Gavarró L, Sauer CM, Sanders DA, Piskorz AM, Couturier DL, Ballereau S, Hernando B, Schneider MP, Hall J, Correia-Martins F, Markowetz F, Macintyre G, Brenton JD. High-grade serous ovarian carcinoma organoids as models of chromosomal instability. Elife. 2023;11(12): e83867. 10.7554/eLife.83867.10.7554/eLife.83867
5. Richardson TE Walker JM Abdullah KG McBrayer SK Viapiano MS Mussa ZM Tsankova NM Snuderl M Hatanpaa KJ Chromosomal instability in adult-type diffuse gliomas Acta Neuropathol Commun 2022 10 1 115 10.1186/s40478-022-01420-w 35978439
Richardson TE, Walker JM, Abdullah KG, McBrayer SK, Viapiano MS, Mussa ZM, Tsankova NM, Snuderl M, Hatanpaa KJ. Chromosomal instability in adult-type diffuse gliomas. Acta Neuropathol Commun. 2022;10(1):115. 10.1186/s40478-022-01420-w.35978439 10.1186/s40478-022-01420-w
6. Maimaiti A Aili Y Turhon M Kadeer K Aikelamu P Wang Z Niu W Aisha M Kasimu M Wang Y Wang Z Modification patterns of DNA methylation-related lncRNAs regulating genomic instability for improving the clinical outcomes and tumour microenvironment characterisation of lower-grade gliomas Front Mol Biosci 2022 10 9 844973 10.3389/fmolb.2022.844973.PMID:35359593;PMCID:PMC8960387
Maimaiti A, Aili Y, Turhon M, Kadeer K, Aikelamu P, Wang Z, Niu W, Aisha M, Kasimu M, Wang Y, Wang Z. Modification patterns of DNA methylation-related lncRNAs regulating genomic instability for improving the clinical outcomes and tumour microenvironment characterisation of lower-grade gliomas. Front Mol Biosci. 2022;10(9): 844973. 10.3389/fmolb.2022.844973.PMID:35359593;PMCID:PMC8960387.10.3389/fmolb.2022.844973.PMID:35359593;PMCID:PMC8960387
7. Donehower LA Soussi T Korkut A Liu Y Schultz A Cardenas M Li X Babur O Hsu TK Lichtarge O Weinstein JN Akbani R Wheeler DA Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas Cell Rep 2019 28 5 1370 1384.e5 10.1016/j.celrep.2019.07.001 31365877
Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, Li X, Babur O, Hsu TK, Lichtarge O, Weinstein JN, Akbani R, Wheeler DA. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep. 2019;28(5):1370-1384.e5. 10.1016/j.celrep.2019.07.001.31365877 10.1016/j.celrep.2019.07.001
8. Rieckhoff J Meyer F Classen S Zielinski A Riepen B Wikman H Petersen C Rothkamm K Borgmann K Parplys AC Exploiting chromosomal instability of PTEN-deficient triple-negative breast cancer cell lines for the sensitization against PARP1 inhibition in a replication-dependent manner Cancers 2020 12 10 2809 10.3390/cancers12102809 33003585
Rieckhoff J, Meyer F, Classen S, Zielinski A, Riepen B, Wikman H, Petersen C, Rothkamm K, Borgmann K, Parplys AC. Exploiting chromosomal instability of PTEN-deficient triple-negative breast cancer cell lines for the sensitization against PARP1 inhibition in a replication-dependent manner. Cancers. 2020;12(10):2809. 10.3390/cancers12102809.33003585 10.3390/cancers12102809
9. Hisamatsu Y Oki E Otsu H Ando K Saeki H Tokunaga E Aishima S Morita M Oda Y Maehara Y Effect of EGFR and p-AKT overexpression on chromosomal instability in gastric cancer Ann Surg Oncol 2016 23 6 1986 1992 10.1245/s10434-016-5097-3 26847684
Hisamatsu Y, Oki E, Otsu H, Ando K, Saeki H, Tokunaga E, Aishima S, Morita M, Oda Y, Maehara Y. Effect of EGFR and p-AKT overexpression on chromosomal instability in gastric cancer. Ann Surg Oncol. 2016;23(6):1986–92. 10.1245/s10434-016-5097-3.26847684 10.1245/s10434-016-5097-3
10. Thompson LL Jeusset LM Lepage CC McManus KJ Evolving therapeutic strategies to exploit chromosome instability in cancer Cancers 2017 9 11 151 10.3390/cancers9110151 29104272
Thompson LL, Jeusset LM, Lepage CC, McManus KJ. Evolving therapeutic strategies to exploit chromosome instability in cancer. Cancers. 2017;9(11):151. 10.3390/cancers9110151.29104272 10.3390/cancers9110151
11. Sahajpal NS Mondal AK Vashisht A Optical genome mapping: integrating structural variations for precise homologous recombination deficiency score calculation Genes 2023 14 9 1683 10.3390/genes14091683 37761823
Sahajpal NS, Mondal AK, Vashisht A, et al. Optical genome mapping: integrating structural variations for precise homologous recombination deficiency score calculation. Genes. 2023;14(9):1683. 10.3390/genes14091683.37761823 10.3390/genes14091683
12. Bakhoum SF Cantley LC The multifaceted role of chromosomal instability in cancer and its microenvironment Cell 2018 174 6 1347 1360 10.1016/j.cell.2018.08.027 30193109
Bakhoum SF, Cantley LC. The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell. 2018;174(6):1347–60. 10.1016/j.cell.2018.08.027.30193109 10.1016/j.cell.2018.08.027
13. Boveri T Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris J Cell Sci 2008 121 1 1 84 10.1242/jcs.025742 18089652
Boveri T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J Cell Sci. 2008;121(1):1–84. 10.1242/jcs.025742.18089652 10.1242/jcs.025742
14. von Hansemann D Über asymmetrische Zellteilung in Epithelkrebsen und deren biologische Bedeutung Virchows Arch Patholog Anat 1890 119 299 326 10.1007/BF01882039
von Hansemann D. Über asymmetrische Zellteilung in Epithelkrebsen und deren biologische Bedeutung. Virchows Arch Patholog Anat. 1890;119:299–326.10.1007/BF01882039
15. Gollin SM Mechanisms leading to chromosomal instability Semin Cancer Biol 2005 15 33 42 10.1016/j.semcancer.2004.09.004 15613286
Gollin SM. Mechanisms leading to chromosomal instability. Semin Cancer Biol. 2005;15:33–42. 10.1016/j.semcancer.2004.09.004.15613286 10.1016/j.semcancer.2004.09.004
16. McGranahan N Burrell RA Endesfelder D Novelli MR Swanton C Cancer chromosomal instability: therapeutic and diagnostic challenges EMBO Rep 2012 13 528 538 10.1038/embor.2012.61 22595889
McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep. 2012;13:528–38. 10.1038/embor.2012.61.22595889 10.1038/embor.2012.61
17. Geigl JB Obenauf AC Schwarzbraun T Speicher MR Defining chromosomal instability Trends Genet 2008 24 64 69 10.1016/j.tig.2007.11.006 18192061
Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR. Defining chromosomal instability. Trends Genet. 2008;24:64–9. 10.1016/j.tig.2007.11.006.18192061 10.1016/j.tig.2007.11.006
18. Vishwakarma R McManus KJ Chromosome instability; implications in cancer development, progression, and clinical outcomes Cancers (Basel) 2020 10.3390/cancers12040824 32235397
Vishwakarma R, McManus KJ. Chromosome instability; implications in cancer development, progression, and clinical outcomes. Cancers (Basel). 2020. 10.3390/cancers12040824.32235397 10.3390/cancers12040824
19. Paulsson K Johansson B High hyperdiploid childhood acute lymphoblastic leukemia Genes Chromosomes Cancer 2009 48 637 660 10.1002/gcc.20671 19415723
Paulsson K, Johansson B. High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2009;48:637–60. 10.1002/gcc.20671.19415723 10.1002/gcc.20671
20. Reifenberger J Reifenberger G Liu L James CD Wechsler W Collins VP Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p Am J Pathol 1994 145 1175 1190 7977648
Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994;145:1175–90.7977648
21. Patterson D Molecular genetic analysis of down syndrome Hum Genet 2009 126 195 214 10.1007/s00439-009-0696-8 19526251
Patterson D. Molecular genetic analysis of down syndrome. Hum Genet. 2009;126:195–214. 10.1007/s00439-009-0696-8.19526251 10.1007/s00439-009-0696-8
22. Crasta K Ganem NJ Dagher R DNA breaks and chromosome pulverization from errors in mitosis Nature 2012 482 53 58 10.1038/nature10802 22258507
Crasta K, Ganem NJ, Dagher R, et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature. 2012;482:53–8.22258507 10.1038/nature10802
23. Karcher S Steiner HH Ahmadi R Different angiogenic phenotypes in primary and secondary glioblastomas Int J Cancer 2006 118 2182 2189 10.1002/ijc.21648 16331629
Karcher S, Steiner HH, Ahmadi R, et al. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer. 2006;118:2182–9.16331629 10.1002/ijc.21648
24. Dokic I Mairani A Brons S High resistance to X-rays and therapeutic carbon ions in glioblastoma cells bearing dysfunctional ATM associates with intrinsic chromosomal instability Int J Radiat Biol 2015 91 157 165 10.3109/09553002.2014.937511 24991884
Dokic I, Mairani A, Brons S, et al. High resistance to X-rays and therapeutic carbon ions in glioblastoma cells bearing dysfunctional ATM associates with intrinsic chromosomal instability. Int J Radiat Biol. 2015;91:157–65.24991884 10.3109/09553002.2014.937511
25. Bochtler T Kartal-Kaess M Granzow M Micronucleus formation in human cancer cells is biased by chromosome size Genes Chromosomes Cancer 2019 58 392 395 10.1002/gcc.22707 30411433
Bochtler T, Kartal-Kaess M, Granzow M, et al. Micronucleus formation in human cancer cells is biased by chromosome size. Genes Chromosomes Cancer. 2019;58:392–5. 10.1002/gcc.22707.30411433 10.1002/gcc.22707
26. Drpic D Almeida AC Aguiar P Chromosome segregation is biased by kinetochore size Curr Biol 2018 28 1344 1356 10.1016/j.cub.2018.03.023 29706521
Drpic D, Almeida AC, Aguiar P, et al. Chromosome segregation is biased by kinetochore size. Curr Biol. 2018;28:1344–56.29706521 10.1016/j.cub.2018.03.023
27. Cai H Chromothripsis DB: a curated database for the documentation, visualization, and mining of chromothripsis data Methods Mol Biol 2018 1769 279 289 10.1007/978-1-4939-7780-2_18 29564831
Cai H. Chromothripsis DB: a curated database for the documentation, visualization, and mining of chromothripsis data. Methods Mol Biol. 2018;1769:279–89.29564831 10.1007/978-1-4939-7780-2_18
28. Duvuru S Sanker V Jain S Sunil Kumar BS Manoj Kumar M Gupta U A rare case of intra-parenchymal meningioma in a female patient who presented with seizures: a case report Clin Case Rep 2023 11 e7927 10.1002/ccr3.7927 37736479
Duvuru S, Sanker V, Jain S, Sunil Kumar BS, Manoj Kumar M, Gupta U. A rare case of intra-parenchymal meningioma in a female patient who presented with seizures: a case report. Clin Case Rep. 2023;11: e7927. 10.1002/ccr3.7927.37736479 10.1002/ccr3.7927
29. van Tilborg AA Al Allak B Velthuizen SC Chromosomal instability in meningiomas J Neuropathol Exp Neurol 2005 64 4 312 322 10.1093/jnen/64.4.312 15835267
van Tilborg AA, Al Allak B, Velthuizen SC, et al. Chromosomal instability in meningiomas. J Neuropathol Exp Neurol. 2005;64(4):312–22. 10.1093/jnen/64.4.312.15835267 10.1093/jnen/64.4.312
30. D’Assoro AB Lingle WL Salisbury JL Centrosome amplification and the development of cancer Oncogene 2002 21 6146 6153 10.1038/sj.onc.1205772 12214243
D’Assoro AB, Lingle WL, Salisbury JL. Centrosome amplification and the development of cancer. Oncogene. 2002;21:6146–53.12214243 10.1038/sj.onc.1205772
31. Doxsey S Duplicating dangerously: linking centrosome duplication and aneuploidy Mol Cell 2002 10 439 440 10.1016/S1097-2765(02)00654-8 12408813
Doxsey S. Duplicating dangerously: linking centrosome duplication and aneuploidy. Mol Cell. 2002;10:439–40.12408813 10.1016/S1097-2765(02)00654-8
32. Kawamura K Izumi H Ma Z Ikeda R Moriyama M Tanaka T Nojima T Levin LS Fujikawa-Yamamoto K Suzuki K Fukasawa K Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression Cancer Res 2004 64 4800 4809 10.1158/0008-5472.CAN-03-3908 15256449
Kawamura K, Izumi H, Ma Z, Ikeda R, Moriyama M, Tanaka T, Nojima T, Levin LS, Fujikawa-Yamamoto K, Suzuki K, Fukasawa K. Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression. Cancer Res. 2004;64:4800–9.15256449 10.1158/0008-5472.CAN-03-3908
33. Doxsey S Re-evaluating centrosome function Nat Rev Mol Cell Biol 2001 2 688 698 10.1038/35089575 11533726
Doxsey S. Re-evaluating centrosome function. Nat Rev Mol Cell Biol. 2001;2:688–98.11533726 10.1038/35089575
34. Fukasawa K Introduction. Centrosome Oncogene 2002 21 6140 6145 10.1038/sj.onc.1205771 12214242
Fukasawa K. Introduction. Centrosome. Oncogene. 2002;21:6140–5.12214242 10.1038/sj.onc.1205771
35. Squatrito M Brennan CW Helmy K Huse JT Petrini JH Holland EC Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas Cancer Cell 2010 18 619 629 10.1016/j.ccr.2010.10.034 21156285
Squatrito M, Brennan CW, Helmy K, Huse JT, Petrini JH, Holland EC. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell. 2010;18:619–29.21156285 10.1016/j.ccr.2010.10.034
36. Golding SE Rosenberg E Valerie N Hussaini I FrigerioM Cockcroft XF Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion Mol Cancer Ther 2009 8 2894 902 10.1158/1535-7163.MCT-09-0519 19808981
Golding SE, Rosenberg E, Valerie N, Hussaini I, FrigerioM Cockcroft XF, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009;8:2894–902.19808981 10.1158/1535-7163.MCT-09-0519
37. Golding SE Rosenberg E Khalil A McEwen A Holmes M Neill S Double strand break repair by homologous recombination is regulated by cell cycle-independent signaling via ATM in human glioma cells J Biol Chem 2004 279 15402 15410 10.1074/jbc.M314191200 14744854
Golding SE, Rosenberg E, Khalil A, McEwen A, Holmes M, Neill S, et al. Double strand break repair by homologous recombination is regulated by cell cycle-independent signaling via ATM in human glioma cells. J Biol Chem. 2004;279:15402–10.14744854 10.1074/jbc.M314191200
38. La Torre D de Divitiis O Conti A Expression of telomeric repeat binding factor-1 in astroglial brain tumors Neurosurgery 2005 56 802 810 10.1227/01.NEU.0000156468.41461.6F 15792519
La Torre D, de Divitiis O, Conti A, et al. Expression of telomeric repeat binding factor-1 in astroglial brain tumors. Neurosurgery. 2005;56:802–10.15792519 10.1227/01.NEU.0000156468.41461.6F
39. Gisselsson D Jonson T Petersen A Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors Proc Natl Acad Sci USA 2001 98 12683 12688 10.1073/pnas.211357798 11675499
Gisselsson D, Jonson T, Petersen A, et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc Natl Acad Sci USA. 2001;98:12683–8.11675499 10.1073/pnas.211357798
40. Hande MP Samper E Lansdorp P Blasco MA Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice J Cell Biol 1999 144 589 601 10.1083/jcb.144.4.589 10037783
Hande MP, Samper E, Lansdorp P, Blasco MA. Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J Cell Biol. 1999;144:589–601.10037783 10.1083/jcb.144.4.589
41. Maser RS DePinho RA Connecting chromosomes, crisis, and cancer Science 2002 297 565 569 10.1126/science.297.5581.565 12142527
Maser RS, DePinho RA. Connecting chromosomes, crisis, and cancer. Science. 2002;297:565–9.12142527 10.1126/science.297.5581.565
42. Rudolph KL Chang S Lee HW Longevity, stress response, and cancer in aging telomerase-deficient mice Cell 1999 96 5 701 712 10.1016/S0092-8674(00)80580-2 10089885
Rudolph KL, Chang S, Lee HW, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell. 1999;96(5):701–12.10089885 10.1016/S0092-8674(00)80580-2
43. Chin L Artandi SE Shen Q p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis Cell 1999 97 527 538 10.1016/S0092-8674(00)80762-X 10338216
Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell. 1999;97:527–38.10338216 10.1016/S0092-8674(00)80762-X
44. Hiraga S Ohnishi T Izumoto S Telomerase activity and alterations in telomere length in human brain tumors Cancer Res 1998 58 2117 2125 9605755
Hiraga S, Ohnishi T, Izumoto S, et al. Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res. 1998;58:2117–25.9605755
45. Le S Zhu JJ Anthony DC Greider CW Black PM Telomerase activity in human gliomas Neurosurgery 1998 42 5 1120 1124 10.1097/00006123-199805000-00099 9588558
Le S, Zhu JJ, Anthony DC, Greider CW, Black PM. Telomerase activity in human gliomas. Neurosurgery. 1998;42(5):1120–4.9588558 10.1097/00006123-199805000-00099
46. Bignold LP Coghlan BL Jersmann HP Hansemann, Boveri, chromosomes and the gametogenesis-related theories of tumours Cell Biol Int 2006 30 640 644 10.1016/j.cellbi.2006.04.002 16753311
Bignold LP, Coghlan BL, Jersmann HP. Hansemann, Boveri, chromosomes and the gametogenesis-related theories of tumours. Cell Biol Int. 2006;30:640–4. 10.1016/j.cellbi.2006.04.002.16753311 10.1016/j.cellbi.2006.04.002
47. Friedlander M Centrioles and centrospheres in giant cells of human gliomas J Submicrosc Cytol 1982 14 401 406 7077718
Friedlander M. Centrioles and centrospheres in giant cells of human gliomas. J Submicrosc Cytol. 1982;14:401–6.7077718
48. Mittal K Kaur J Jaczko M Wei G Toss MS Rakha EA Janssen EAM Søiland H Kucuk O Reid MD Gupta MV Aneja R Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies Cancer Metastasis Rev 2021 40 1 319 339 10.1007/s10555-020-09937-z 33106971
Mittal K, Kaur J, Jaczko M, Wei G, Toss MS, Rakha EA, Janssen EAM, Søiland H, Kucuk O, Reid MD, Gupta MV, Aneja R. Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies. Cancer Metastasis Rev. 2021;40(1):319–39. 10.1007/s10555-020-09937-z.33106971 10.1007/s10555-020-09937-z
49. Levine MS Bakker B Boeckx B Moyett J Lu J Vitre B Spierings DC Lansdorp PM Cleveland DW Lambrechts D Foijer F Holland AJ Centrosome amplification is sufficient to promote spontaneous tumorigenesis in mammals Dev Cell 2017 40 3 313 322.e5 10.1016/j.devcel.2016.12.022 28132847
Levine MS, Bakker B, Boeckx B, Moyett J, Lu J, Vitre B, Spierings DC, Lansdorp PM, Cleveland DW, Lambrechts D, Foijer F, Holland AJ. Centrosome amplification is sufficient to promote spontaneous tumorigenesis in mammals. Dev Cell. 2017;40(3):313-322.e5. 10.1016/j.devcel.2016.12.022.28132847 10.1016/j.devcel.2016.12.022
50. Coumar MS Cheung CH Chang JY Hsieh HP Advances in Aurora kinase inhibitor patents Expert Opin Ther Pat 2009 19 321 356 10.1517/13543770802646949 19441907
Coumar MS, Cheung CH, Chang JY, Hsieh HP. Advances in Aurora kinase inhibitor patents. Expert Opin Ther Pat. 2009;19:321–56. 10.1517/13543770802646949.19441907 10.1517/13543770802646949
51. Cheung CH Coumar MS Hsieh HP Chang JY Aurora kinase inhibitors in preclinical and clinical testing Expert Opin Investig Drugs 2009 18 379 398 10.1517/13543780902806392 19335272
Cheung CH, Coumar MS, Hsieh HP, Chang JY. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs. 2009;18:379–98. 10.1517/13543780902806392.19335272 10.1517/13543780902806392
52. Kollareddy M Dzubak P Zheleva D Hajduch M Aurora kinases: structure, functions and their association with cancer Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008 152 27 33 10.5507/bp.2008.004 18795071
Kollareddy M, Dzubak P, Zheleva D, Hajduch M. Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152:27–33.18795071 10.5507/bp.2008.004
53. Rulseh AM Keller J Klener J Sroubek J Dbalý V Syrůček M Tovaryš F Vymazal J Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields World J Surg Oncol 2012 10 220 10.1186/1477-7819-10-220 23095807
Rulseh AM, Keller J, Klener J, Sroubek J, Dbalý V, Syrůček M, Tovaryš F, Vymazal J. Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields. World J Surg Oncol. 2012;10:220. 10.1186/1477-7819-10-220.23095807 10.1186/1477-7819-10-220
54. Ramos-Fresnedo A Pullen MW Perez-Vega C Domingo RA Akinduro OO Almeida JP Suarez-Meade P Marenco-Hillembrand L Jentoft ME Bendok BR Trifiletti DM Chaichana KL Porter AB Quiñones-Hinojosa A Burns TC Kizilbash SH Middlebrooks EH Sherman WJ The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study J Neurooncol 2022 157 1 177 185 10.1007/s11060-022-03960-6 35175545
Ramos-Fresnedo A, Pullen MW, Perez-Vega C, Domingo RA, Akinduro OO, Almeida JP, Suarez-Meade P, Marenco-Hillembrand L, Jentoft ME, Bendok BR, Trifiletti DM, Chaichana KL, Porter AB, Quiñones-Hinojosa A, Burns TC, Kizilbash SH, Middlebrooks EH, Sherman WJ. The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study. J Neurooncol. 2022;157(1):177–85. 10.1007/s11060-022-03960-6.35175545 10.1007/s11060-022-03960-6
55. Luo S Zhang Y Jia Y Zhang X Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns Neuropathol Appl Neurobiol 2022 48 6 e12831 10.1111/nan.12831 35767937
Luo S, Zhang Y, Jia Y, Zhang X. Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns. Neuropathol Appl Neurobiol. 2022;48(6): e12831. 10.1111/nan.12831.35767937 10.1111/nan.12831
56. Oh S Yeom J Cho HJ Kim J Yoon S Kim H Sa JK Ju S Lee H Oh MJ Lee W Kwon Y Li H Choi S Han JH Chang JH Choi E Kim J Her N Kim HS Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wildtype glioblastoma with prognostic and therapeutic opportunities Nat Commun 2020 11 1 1 16 10.1038/s41467-020-17139-y 31911652
Oh S, Yeom J, Cho HJ, Kim J, Yoon S, Kim H, Sa JK, Ju S, Lee H, Oh MJ, Lee W, Kwon Y, Li H, Choi S, Han JH, Chang JH, Choi E, Kim J, Her N, Kim HS. Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wildtype glioblastoma with prognostic and therapeutic opportunities. Nat Commun. 2020;11(1):1–16. 10.1038/s41467-020-17139-y.31911652 10.1038/s41467-020-17139-y
57. Raviram R Raman A Preissl S Ning J Wu S Koga T Zhang K Brennan CW Zhu C Luebeck J Van Deynze K Han JY Hou X Ye Z Mischel AK Li YE Fang R Baback T Mugford J Han CZ Chen CC Integrated analysis of single-cell chromatin state and transcriptome identified common vulnerability despite glioblastoma heterogeneity Proc Natl Acad Sci USA 2023 120 20 e2210991120 10.1073/pnas.2210991120 37155843
Raviram R, Raman A, Preissl S, Ning J, Wu S, Koga T, Zhang K, Brennan CW, Zhu C, Luebeck J, Van Deynze K, Han JY, Hou X, Ye Z, Mischel AK, Li YE, Fang R, Baback T, Mugford J, Han CZ, Chen CC. Integrated analysis of single-cell chromatin state and transcriptome identified common vulnerability despite glioblastoma heterogeneity. Proc Natl Acad Sci USA. 2023;120(20):e2210991120. 10.1073/pnas.2210991120.37155843 10.1073/pnas.2210991120
58. Cosper PF Copeland SE Tucker JB Weaver BA Chromosome missegregation as a modulator of radiation sensitivity Sem Rad Oncol 2022 32 1 54 63 10.1016/j.semradonc.2021.09.002
Cosper PF, Copeland SE, Tucker JB, Weaver BA. Chromosome missegregation as a modulator of radiation sensitivity. Sem Rad Oncol. 2022;32(1):54–63. 10.1016/j.semradonc.2021.09.002.10.1016/j.semradonc.2021.09.002
59. Nobusawa S Watanabe T Kleihues P Ohgaki H IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas Clin Cancer Res 2009 15 19 6002 6007 10.1158/1078-0432.CCR-09-0715 19755387
Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002–7. 10.1158/1078-0432.CCR-09-0715.19755387 10.1158/1078-0432.CCR-09-0715
60. Körber V Yang J Barah P Wu Y Stichel D Gu Z Fletcher MNC Jones D Hentschel B Lamszus K Tonn JC Schackert G Sabel M Felsberg J Zacher A Kaulich K Hübschmann D Herold-Mende C von Deimling A Weller M Lichter P Evolutionary trajectories of IDHWT glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis Cancer cell 2019 35 4 692 704.e12 10.1016/j.ccell.2019.02.007 30905762
Körber V, Yang J, Barah P, Wu Y, Stichel D, Gu Z, Fletcher MNC, Jones D, Hentschel B, Lamszus K, Tonn JC, Schackert G, Sabel M, Felsberg J, Zacher A, Kaulich K, Hübschmann D, Herold-Mende C, von Deimling A, Weller M, Lichter P. Evolutionary trajectories of IDHWT glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. Cancer cell. 2019;35(4):692-704.e12. 10.1016/j.ccell.2019.02.007.30905762 10.1016/j.ccell.2019.02.007
61. Nathanson DA Gini B Mottahedeh J Visnyei K Koga T Gomez G Eskin A Hwang K Wang J Masui K Paucar A Yang H Ohashi M Zhu S Wykosky J Reed R Nelson SF Cloughesy TF James CD Rao PN Mischel PS Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA Science 2014 343 6166 72 76 10.1126/science.1241328 24310612
Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Mischel PS. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014;343(6166):72–6. 10.1126/science.1241328.24310612 10.1126/science.1241328
62. Barresi V Simbolo M Mafficini A Martini M Calicchia M Piredda ML Ciaparrone C Bonizzato G Ammendola S Caffo M Pinna G Sala F Lawlor RT Ghimenton C Scarpa A IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation Acta Neuropathol Commun 2021 9 1 200 10.1186/s40478-021-01304-5 34952640
Barresi V, Simbolo M, Mafficini A, Martini M, Calicchia M, Piredda ML, Ciaparrone C, Bonizzato G, Ammendola S, Caffo M, Pinna G, Sala F, Lawlor RT, Ghimenton C, Scarpa A. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation. Acta Neuropathol Commun. 2021;9(1):200. 10.1186/s40478-021-01304-5.34952640 10.1186/s40478-021-01304-5
63. Hsu EJ Thomas J Maher EA Impact of CDKN2A/B, MTAP, and TERT genetic alterations on survival in IDH Wild Type glioblastomas Discov Onc 2022 13 126 10.1007/s12672-022-00590-2
Hsu EJ, Thomas J, Maher EA, et al. Impact of CDKN2A/B, MTAP, and TERT genetic alterations on survival in IDH Wild Type glioblastomas. Discov Onc. 2022;13:126. 10.1007/s12672-022-00590-2.10.1007/s12672-022-00590-2
64. Esileanu CMS Dirven L Wijnenga MMJ Koekkoek JAF Vincent AJPE Dubbink HJ Atmodimedjo PN Kros JM van Duinen SG Smits M Taphoorn MJB French PJ van den Bent MJ Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria Neuro-oncology 2020 22 4 515 523 10.1093/neuonc/noz200 31637414
Esileanu CMS, Dirven L, Wijnenga MMJ, Koekkoek JAF, Vincent AJPE, Dubbink HJ, Atmodimedjo PN, Kros JM, van Duinen SG, Smits M, Taphoorn MJB, French PJ, van den Bent MJ. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro-oncology. 2020;22(4):515–23. 10.1093/neuonc/noz200.31637414 10.1093/neuonc/noz200
65. Wong QH Li KK Wang W Malta TM Noushmehr H Grabovska Y Jones C Chan AK Kwan JS Huang QJ Wong GC Li W Liu X Chen H Chan DT Mao Y Zhang Z Shi Z Ng H Molecular landscape of IDH-mutant primary astrocytoma grade IV/glioblastomas Mod Pathol 2021 34 7 1245 1260 10.1038/s41379-021-00778-x 33692446
Wong QH, Li KK, Wang W, Malta TM, Noushmehr H, Grabovska Y, Jones C, Chan AK, Kwan JS, Huang QJ, Wong GC, Li W, Liu X, Chen H, Chan DT, Mao Y, Zhang Z, Shi Z, Ng H. Molecular landscape of IDH-mutant primary astrocytoma grade IV/glioblastomas. Mod Pathol. 2021;34(7):1245–60. 10.1038/s41379-021-00778-x.33692446 10.1038/s41379-021-00778-x
66. Kurdi M Mulla N Katib Y Alsinani T Hakamy S Addas MJB Malibary H Halawa TF Farhan SM Faizo E Baeesa S The cancer driver genes IDH1 and IDH2 and CD204 in WHO-grade 4 astrocytoma: crosstalk between cancer metabolism and tumour associated macrophage recruitment in tumour microenvironment Biologics 2023 17 15 22 10.2147/BTT.S394556 36778762
Kurdi M, Mulla N, Katib Y, Alsinani T, Hakamy S, Addas MJB, Malibary H, Halawa TF, Farhan SM, Faizo E, Baeesa S. The cancer driver genes IDH1 and IDH2 and CD204 in WHO-grade 4 astrocytoma: crosstalk between cancer metabolism and tumour associated macrophage recruitment in tumour microenvironment. Biologics. 2023;17:15–22. 10.2147/BTT.S394556.36778762 10.2147/BTT.S394556
67. Bledea R Vasudevaraja V Patel S Stafford J Serrano J Esposito G Tredwin LM Goodman N Kloetgen A Golfinos JG Zagzag D Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers Sci Rep 2019 9 1 1 12 10.1038/s41598-019-53262-7 30626917
Bledea R, Vasudevaraja V, Patel S, Stafford J, Serrano J, Esposito G, Tredwin LM, Goodman N, Kloetgen A, Golfinos JG, Zagzag D. Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. Sci Rep. 2019;9(1):1–12. 10.1038/s41598-019-53262-7.30626917 10.1038/s41598-019-53262-7
68. Suwala AK Stichel D Schrimpf D Kloor M Wefers AK Reinhardt A Maas SLN Kratz CP Schweizer L Hasselblatt M Snuderl M Abedalthagafi MSJ Abdullaev Z Monoranu CM Bergmann M Pekrun A Freyschlag C Aronica E Kramm CM Hinz F Reuss DE Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis Acta Neuropathol 2021 141 1 85 100 10.1007/s00401-020-02243-6 33216206
Suwala AK, Stichel D, Schrimpf D, Kloor M, Wefers AK, Reinhardt A, Maas SLN, Kratz CP, Schweizer L, Hasselblatt M, Snuderl M, Abedalthagafi MSJ, Abdullaev Z, Monoranu CM, Bergmann M, Pekrun A, Freyschlag C, Aronica E, Kramm CM, Hinz F, Reuss DE. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathol. 2021;141(1):85–100. 10.1007/s00401-020-02243-6.33216206 10.1007/s00401-020-02243-6
69. Liu Y Sathe AA Abdullah KG Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas Acta Neuropathol Commun 2022 10 32 10.1186/s40478-022-01339-2 35264242
Liu Y, Sathe AA, Abdullah KG, et al. Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas. Acta Neuropathol Commun. 2022;10:32. 10.1186/s40478-022-01339-2.35264242 10.1186/s40478-022-01339-2
70. Hu Y Ru N Xiao H Chaturbedi A Hoa NT Tian XJ Zhang H Ke C Yan F Nelson J Li Z Gramer R Yu L Siegel E Zhang X Jia Z Jadus MR Limoli CL Linskey ME Xing J Zhou YH Tumor-specific chromosome mis-segregation controls cancer plasticity by maintaining tumor heterogeneity PloS one 2013 8 11 e80898 10.1371/journal.pone.0080898 24282558
Hu Y, Ru N, Xiao H, Chaturbedi A, Hoa NT, Tian XJ, Zhang H, Ke C, Yan F, Nelson J, Li Z, Gramer R, Yu L, Siegel E, Zhang X, Jia Z, Jadus MR, Limoli CL, Linskey ME, Xing J, Zhou YH. Tumor-specific chromosome mis-segregation controls cancer plasticity by maintaining tumor heterogeneity. PloS one. 2013;8(11):e80898. 10.1371/journal.pone.0080898.24282558 10.1371/journal.pone.0080898
71. Wei Y Li G Feng J Stalled oligodendrocyte differentiation in IDH-mutant gliomas Genome Med 2023 15 24 10.1186/s13073-023-01175-6 37055795
Wei Y, Li G, Feng J, et al. Stalled oligodendrocyte differentiation in IDH-mutant gliomas. Genome Med. 2023;15:24. 10.1186/s13073-023-01175-6.37055795 10.1186/s13073-023-01175-6
72. Pekmezci M Rice T Molinaro AM Walsh KM Decker PA Hansen H Sicotte H Kollmeyer TM McCoy LS Sarkar G Perry A Giannini C Tihan T Berger MS Wiemels JL Bracci PM Eckel-Passow JE Lachance DH Clarke J Taylor JW Wrensch MR Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT Acta Neuropathol 2017 133 6 1001 1016 10.1007/s00401-017-1690-1 28255664
Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Wrensch MR. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017;133(6):1001–16. 10.1007/s00401-017-1690-1.28255664 10.1007/s00401-017-1690-1
73. Fukuoka K Mamatjan Y Ryall S Komosa M Bennett J Zapotocky M Keith J Myrehaug S Hazrati LN Aldape K Laperriere N Bouffet E Tabori U Hawkins C BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults Brain Pathol 2020 30 3 515 523 10.1111/bpa.12799 31630459
Fukuoka K, Mamatjan Y, Ryall S, Komosa M, Bennett J, Zapotocky M, Keith J, Myrehaug S, Hazrati LN, Aldape K, Laperriere N, Bouffet E, Tabori U, Hawkins C. BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults. Brain Pathol. 2020;30(3):515–23. 10.1111/bpa.12799.31630459 10.1111/bpa.12799
74. Nigro JM Takahashi MA Ginzinger DG Law M Passe S Jenkins RB Aldape K Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay Am J Pathol 2001 158 4 1253 1262 10.1016/S0002-9440(10)64076-X 11290543
Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol. 2001;158(4):1253–62. 10.1016/S0002-9440(10)64076-X.11290543 10.1016/S0002-9440(10)64076-X
75. Lassaletta A Zapotocky M Mistry M Ramaswamy V Honnorat M Krishnatry R Guerreiro Stucklin A Zhukova N Arnoldo A Ryall S Ling C McKeown T Loukides J Cruz O de Torres C Ho CY Packer RJ Tatevossian R Qaddoumi I Harreld JH Tabori U Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas J Clin Oncol 2017 35 25 2934 2941 10.1200/JCO.2016.71.8726 28727518
Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Guerreiro Stucklin A, Zhukova N, Arnoldo A, Ryall S, Ling C, McKeown T, Loukides J, Cruz O, de Torres C, Ho CY, Packer RJ, Tatevossian R, Qaddoumi I, Harreld JH, Tabori U. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol. 2017;35(25):2934–41. 10.1200/JCO.2016.71.8726.28727518 10.1200/JCO.2016.71.8726
76. Sahm F Schrimpf D Jones DT Meyer J Kratz A Reuss D Capper D Koelsche C Korshunov A Wiestler B Buchhalter I Milde T Selt F Sturm D Kool M Hummel M Bewerunge-Hudler M Mawrin C Schüller U Jungk C von Deimling A Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets Acta Neuropathol 2016 131 6 903 910 10.1007/s00401-015-1519-8 26671409
Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D, Capper D, Koelsche C, Korshunov A, Wiestler B, Buchhalter I, Milde T, Selt F, Sturm D, Kool M, Hummel M, Bewerunge-Hudler M, Mawrin C, Schüller U, Jungk C, von Deimling A. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2016;131(6):903–10. 10.1007/s00401-015-1519-8.26671409 10.1007/s00401-015-1519-8
77. Zhang J Wu G Miller CP Tatevossian RG Dalton JD Tang B Orisme W Punchihewa C Parker M Qaddoumi I Boop FA Lu C Kandoth C Ding L Lee R Huether R Chen X Hedlund E Nagahawatte P Rusch M St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas Nat Genet 2013 45 6 602 612 10.1038/ng.2611 23583981
Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, Boop FA, Lu C, Kandoth C, Ding L, Lee R, Huether R, Chen X, Hedlund E, Nagahawatte P, Rusch M, St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45(6):602–12. 10.1038/ng.2611.23583981 10.1038/ng.2611
78. Zhang H Liu K Ba R Zhang Z Zhang Y Chen Y Gu W Shen Z Shu Q Fu J Wu D Histological and molecular classifications of pediatric glioma with time-dependent diffusion MRI-based microstructural mapping Neuro Oncol 2023 25 6 1146 1156 10.1093/neuonc/noad003 36617263
Zhang H, Liu K, Ba R, Zhang Z, Zhang Y, Chen Y, Gu W, Shen Z, Shu Q, Fu J, Wu D. Histological and molecular classifications of pediatric glioma with time-dependent diffusion MRI-based microstructural mapping. Neuro Oncol. 2023;25(6):1146–56. 10.1093/neuonc/noad003.36617263 10.1093/neuonc/noad003
79. Louis DN Perry A Wesseling P Brat DJ Cree IA Figarella-Branger D Hawkins C Ng HK Pfister SM Reifenberger G Soffietti R von Deimling A Ellison DW The 2021 WHO classification of tumors of the central nervous system: a summary Neuro Oncol 2021 23 8 1231 1251 10.1093/neuonc/noab106 34185076
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51. 10.1093/neuonc/noab106.34185076 10.1093/neuonc/noab106
80. Wang AC Jones DTW Abecassis IJ Cole BL Leary SES Lockwood CM Chavez L Capper D Korshunov A Fallah A Wang S Ene C Olson JM Geyer JR Holland EC Lee A Ellenbogen RG Ojemann JG Desmoplastic infantile ganglioglioma/astrocytoma (DIG/DIA) are distinct entities with frequent BRAFV600 mutations Mol Cancer Res 2018 16 10 1491 1498 10.1158/1541-7786.MCR-17-0507 30006355
Wang AC, Jones DTW, Abecassis IJ, Cole BL, Leary SES, Lockwood CM, Chavez L, Capper D, Korshunov A, Fallah A, Wang S, Ene C, Olson JM, Geyer JR, Holland EC, Lee A, Ellenbogen RG, Ojemann JG. Desmoplastic infantile ganglioglioma/astrocytoma (DIG/DIA) are distinct entities with frequent BRAFV600 mutations. Mol Cancer Res. 2018;16(10):1491–8. 10.1158/1541-7786.MCR-17-0507.30006355 10.1158/1541-7786.MCR-17-0507
81. Sugiyama K Arita K Shima T Nakaoka M Matsuoka T Taniguchi E Okamura T Yamasaki H Kajiwara Y Kurisu K Good clinical course in infants with desmoplastic cerebral neuroepithelial tumor treated by surgery alone J Neurooncol 2002 59 1 63 69 10.1023/a:1016309813752 12222839
Sugiyama K, Arita K, Shima T, Nakaoka M, Matsuoka T, Taniguchi E, Okamura T, Yamasaki H, Kajiwara Y, Kurisu K. Good clinical course in infants with desmoplastic cerebral neuroepithelial tumor treated by surgery alone. J Neurooncol. 2002;59(1):63–9. 10.1023/a:1016309813752.12222839 10.1023/a:1016309813752
82. Cerdá-Nicolás M Lopez-Gines C Gil-Benso R Desmoplastic infantile ganglioglioma: Morphological, immunohistochemical and genetic features Histopathology 2006 81 617 621
Cerdá-Nicolás M, Lopez-Gines C, Gil-Benso R, et al. Desmoplastic infantile ganglioglioma: Morphological, immunohistochemical and genetic features. Histopathology. 2006;81:617–21.
83. Lönnrot K Terho M Kähärä V Desmoplastic infantile ganglioglioma: novel aspects in clinical presentation and genetics Surg Neurol 2007 68 304 308 10.1016/j.surneu.2006.11.043 17719974
Lönnrot K, Terho M, Kähärä V, et al. Desmoplastic infantile ganglioglioma: novel aspects in clinical presentation and genetics. Surg Neurol. 2007;68:304–8.17719974 10.1016/j.surneu.2006.11.043
84. Park JP Dossu JR Rhodes CH Telomere associations in desmoplastic infantile ganglioglioma Cancer Genet Cytogenet 1996 92 4 7 10.1016/S0165-4608(96)00166-5 8956861
Park JP, Dossu JR, Rhodes CH. Telomere associations in desmoplastic infantile ganglioglioma. Cancer Genet Cytogenet. 1996;92:4–7.8956861 10.1016/S0165-4608(96)00166-5
85. Kros JM Delwel EJ de Jong TH Desmoplastic infantile astrocytoma and ganglioglioma: a search for genomic characteristics Acta Neuropathol 2002 104 144 48 10.1007/s00401-002-0534-8 12111357
Kros JM, Delwel EJ, de Jong TH, et al. Desmoplastic infantile astrocytoma and ganglioglioma: a search for genomic characteristics. Acta Neuropathol. 2002;104:144–8.12111357 10.1007/s00401-002-0534-8
86. Gessi M Zur Mühlen A Hammes J Waha A Denkhaus D Pietsch T Genome-wide DNA copy number analysis of desmoplastic infantile astrocytomas and desmoplastic infantile gangliogliomas J Neuropathol Exp Neurol 2013 72 9 807 815 10.1097/NEN.0b013e3182a033a0 23965740
Gessi M, Zur Mühlen A, Hammes J, Waha A, Denkhaus D, Pietsch T. Genome-wide DNA copy number analysis of desmoplastic infantile astrocytomas and desmoplastic infantile gangliogliomas. J Neuropathol Exp Neurol. 2013;72(9):807–15. 10.1097/NEN.0b013e3182a033a0.23965740 10.1097/NEN.0b013e3182a033a0
87. Hernández-Hernández A López-Santaella T Torres-Caballero A Serrato A Torres-Flores U Montesinos-Valencia D Chico-Ponce de León F González-Carranza V Torres-García S Rebollar-Vega R De la Rosa-Velázquez IA Ortiz R Pérez-Ramírez M García-Hernández N García-Méndez A Arenas-Huertero F The transcriptomic landscape of pediatric astrocytoma Int J Mol Sci 2022 23 20 12696 10.3390/ijms232012696 36293551
Hernández-Hernández A, López-Santaella T, Torres-Caballero A, Serrato A, Torres-Flores U, Montesinos-Valencia D, Chico-Ponce de León F, González-Carranza V, Torres-García S, Rebollar-Vega R, De la Rosa-Velázquez IA, Ortiz R, Pérez-Ramírez M, García-Hernández N, García-Méndez A, Arenas-Huertero F. The transcriptomic landscape of pediatric astrocytoma. Int J Mol Sci. 2022;23(20):12696. 10.3390/ijms232012696.36293551 10.3390/ijms232012696
88. López GY Perry A Harding B Li M Santi M CDKN2A/B loss is associated with anaplastic transformation in a case of NTRK2 fusion-positive pilocytic astrocytoma Neuropathol Appl Neurobiol 2019 45 2 174 178 10.1111/nan.12503 29804288
López GY, Perry A, Harding B, Li M, Santi M. CDKN2A/B loss is associated with anaplastic transformation in a case of NTRK2 fusion-positive pilocytic astrocytoma. Neuropathol Appl Neurobiol. 2019;45(2):174–8. 10.1111/nan.12503.29804288 10.1111/nan.12503
89. Grau E Balaguer J Canete A Subtelomeric analysis of pediatric astrocytoma: subchromosomal instability is a distinctive feature of pleomorphic xanthoastrocytoma J Neurooncol 2009 93 175 182 10.1007/s11060-008-9763-6 19099200
Grau E, Balaguer J, Canete A, et al. Subtelomeric analysis of pediatric astrocytoma: subchromosomal instability is a distinctive feature of pleomorphic xanthoastrocytoma. J Neurooncol. 2009;93:175–82. 10.1007/s11060-008-9763-6.19099200 10.1007/s11060-008-9763-6
90. Rickert CH Sträter R Kaatsch P Wassmann H Jürgens H Dockhorn-Dworniczak B Paulus W Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases Am J Pathol 2001 158 4 1525 1532 10.1016/S0002-9440(10)64103-X 11290570
Rickert CH, Sträter R, Kaatsch P, Wassmann H, Jürgens H, Dockhorn-Dworniczak B, Paulus W. Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol. 2001;158(4):1525–32. 10.1016/S0002-9440(10)64103-X.11290570 10.1016/S0002-9440(10)64103-X
91. Yang W Porras JL Khalafallah AM Sun Y Bettegowda A Mukherjee D Comparison of adult and pediatric pilocytic astrocytomas using competing risk analysis: a population-based study Clin Neurol Neurosurg 2022 1 212 107084 107094 10.1016/j.clineuro.2021.107084
Yang W, Porras JL, Khalafallah AM, Sun Y, Bettegowda A, Mukherjee D. Comparison of adult and pediatric pilocytic astrocytomas using competing risk analysis: a population-based study. Clin Neurol Neurosurg. 2022;1(212):107084–94.10.1016/j.clineuro.2021.107084
92. Tripathi R Modur V Senovilla L Kroemer G Komurov K Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion Oncoimmunology 2019 8 11 1657374 10.1080/2162402X.2019.1657374 31646083
Tripathi R, Modur V, Senovilla L, Kroemer G, Komurov K. Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion. Oncoimmunology. 2019;8(11):1657374. 10.1080/2162402X.2019.1657374.31646083 10.1080/2162402X.2019.1657374
93. Levine AB Nobre L Das A Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment Nat Commun 2024 15 1 5790 10.1038/s41467-024-49595-1 38987542
Levine AB, Nobre L, Das A, et al. Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment. Nat Commun. 2024;15(1):5790. 10.1038/s41467-024-49595-1.38987542 10.1038/s41467-024-49595-1
94. Shalaby A Shalaby O Abdullah H Boulassel MR Arafa M Correlation of PD-L1 expression with different clinico-pathological and immunohistochemical features of ovarian surface epithelial tumors Clin Transl Oncol 2024 10.1007/s12094-024-03613-2 39090421
Shalaby A, Shalaby O, Abdullah H, Boulassel MR, Arafa M. Correlation of PD-L1 expression with different clinico-pathological and immunohistochemical features of ovarian surface epithelial tumors. Clin Transl Oncol. 2024. 10.1007/s12094-024-03613-2.39090421 10.1007/s12094-024-03613-2
95. Zhao M Wang Q Wang Q Jia P Zhao Z Computational tools for copy number variation (CNV) detection using next-generation sequencing data: features andperspectives BMC Bioinf 2013 14 S1 10.1186/1471-2105-14-S11-S1
Zhao M, Wang Q, Wang Q, Jia P, Zhao Z. Computational tools for copy number variation (CNV) detection using next-generation sequencing data: features andperspectives. BMC Bioinf. 2013;14:S1. 10.1186/1471-2105-14-S11-S1.10.1186/1471-2105-14-S11-S1
96. Bhuvaneshwar K Belouali A Singh V G-DOC Plus: an integrative bioinformatics platform for precision medicine BMC Bioinf 2016 17 193 10.1186/s12859-016-1010-0
Bhuvaneshwar K, Belouali A, Singh V, et al. G-DOC Plus: an integrative bioinformatics platform for precision medicine. BMC Bioinf. 2016;17:193. 10.1186/s12859-016-1010-0.10.1186/s12859-016-1010-0
97. Song L Bhuvaneshwar K Wang Y Feng Y Shih I-M Madhavan S Gusev Y CINdex: a bioconductor package for analysis of chromosome instability in DNA copy number data Cancer Inf 2017 16 1176935117746637 10.1177/1176935117746637
Song L, Bhuvaneshwar K, Wang Y, Feng Y, Shih I-M, Madhavan S, Gusev Y. CINdex: a bioconductor package for analysis of chromosome instability in DNA copy number data. Cancer Inf. 2017;16:1176935117746637. 10.1177/1176935117746637.10.1177/1176935117746637
98. Gao R Fu ZC Li X Wang Y Wei J Li G Wang L Wu J Huang X Yang L Chen J Genomic and transcriptomic analyses of prime editing guide rna-independent off-target effects by prime editors CRISPR J 2022 5 2 276 293 10.1089/crispr.2021.0080 35294852
Gao R, Fu ZC, Li X, Wang Y, Wei J, Li G, Wang L, Wu J, Huang X, Yang L, Chen J. Genomic and transcriptomic analyses of prime editing guide rna-independent off-target effects by prime editors. CRISPR J. 2022;5(2):276–93. 10.1089/crispr.2021.0080.35294852 10.1089/crispr.2021.0080
99. Liang J Lv X Lu C Ye X Chen X Fu J Luo C Zhao Y Prognostic factors of patients with gliomas—an analysis on 335 patients with Glioblastoma and other forms of Gliomas BMC Cancer 2020 10.1186/s12885-019-6511-6 33243205
Liang J, Lv X, Lu C, Ye X, Chen X, Fu J, Luo C, Zhao Y. Prognostic factors of patients with gliomas—an analysis on 335 patients with Glioblastoma and other forms of Gliomas. BMC Cancer. 2020. 10.1186/s12885-019-6511-6.33243205 10.1186/s12885-019-6511-6
100. Goldbrunner R Ruge M Kocher M Lucas CW The treatment of gliomas in adulthood Dtsch Arztebl Int 2018 115 20–21 356 364 10.3238/arztebl.2018.0356 29914619
Goldbrunner R, Ruge M, Kocher M, Lucas CW. The treatment of gliomas in adulthood. Dtsch Arztebl Int. 2018;115(20–21):356–64. 10.3238/arztebl.2018.0356.29914619 10.3238/arztebl.2018.0356
101. Hong C Schubert M Tijhuis AE Requesens M Roorda M Ruiz LA Bakker PL Pieters W Chen M Wardenaar R Spierings DC De Bruyn M Van Vugt MA Foijer F CGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers Nature 2022 607 7918 366 373 10.1038/s41586-022-04847-2 35705809
Hong C, Schubert M, Tijhuis AE, Requesens M, Roorda M, Ruiz LA, Bakker PL, Pieters W, Chen M, Wardenaar R, Spierings DC, De Bruyn M, Van Vugt MA, Foijer F. CGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers. Nature. 2022;607(7918):366–73. 10.1038/s41586-022-04847-2.35705809 10.1038/s41586-022-04847-2
102. Lombardi G Barresi V Indraccolo S Simbolo M Fassan M Mandruzzato S Simonelli M Caccese M Pizzi M Fassina A Padovan M Masetto E Gardiman MP Bonavina MG Caffo M Persico P Chioffi F Denaro L Dei Tos AP Scarpa A Zagonel V Pembrolizumab activity in recurrent high-grade gliomas with partial or complete loss of mismatch repair protein expression: a monocentric, observational and prospective pilot study Cancers 2020 12 8 2283 10.3390/cancers12082283 32823925
Lombardi G, Barresi V, Indraccolo S, Simbolo M, Fassan M, Mandruzzato S, Simonelli M, Caccese M, Pizzi M, Fassina A, Padovan M, Masetto E, Gardiman MP, Bonavina MG, Caffo M, Persico P, Chioffi F, Denaro L, Dei Tos AP, Scarpa A, Zagonel V. Pembrolizumab activity in recurrent high-grade gliomas with partial or complete loss of mismatch repair protein expression: a monocentric, observational and prospective pilot study. Cancers. 2020;12(8):2283. 10.3390/cancers12082283.32823925 10.3390/cancers12082283
103. Wang Y Drum DL Sun R Zhang Y Chen F Sun F Dal E Yu L Jia J Arya S Jia L Fan S Isakoff SJ Kehlmann AM Dotti G Liu F Zheng H Ferrone CR Taghian AG Wang X Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment Nat Commun 2023 14 1 1 17 10.1038/s41467-023-41282-x 36596776
Wang Y, Drum DL, Sun R, Zhang Y, Chen F, Sun F, Dal E, Yu L, Jia J, Arya S, Jia L, Fan S, Isakoff SJ, Kehlmann AM, Dotti G, Liu F, Zheng H, Ferrone CR, Taghian AG, Wang X. Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment. Nat Commun. 2023;14(1):1–17. 10.1038/s41467-023-41282-x.36596776 10.1038/s41467-023-41282-x
104. Eckerdt FD Bell JB Gonzalez C Oh MS Perez RE Mazewski C Fischietti M Goldman S Nakano I Platanias LC Combined PI3Kα-mTOR targeting of glioma stem cells Sci Rep 2020 10 1 1 11 10.1038/s41598-020-78788-z 31913322
Eckerdt FD, Bell JB, Gonzalez C, Oh MS, Perez RE, Mazewski C, Fischietti M, Goldman S, Nakano I, Platanias LC. Combined PI3Kα-mTOR targeting of glioma stem cells. Sci Rep. 2020;10(1):1–11. 10.1038/s41598-020-78788-z.31913322 10.1038/s41598-020-78788-z
105. Wenger A Karlsson I Kling T Carén H CRISPR-Cas9 knockout screen identifies novel treatment targets in childhood high-grade glioma Clin Epigenetics 2023 15 1 80 10.1186/s13148-023-01498-6 37161535
Wenger A, Karlsson I, Kling T, Carén H. CRISPR-Cas9 knockout screen identifies novel treatment targets in childhood high-grade glioma. Clin Epigenetics. 2023;15(1):80. 10.1186/s13148-023-01498-6.37161535 10.1186/s13148-023-01498-6
106. Golas MM Gunawan B Cakir M Cameron S Enders C Liersch T Füzesi L Sander B Evolutionary patterns of chromosomal instability and mismatch repair deficiency in proximal and distal colorectal cancer Colorectal Dis 2022 24 2 157 176 10.1111/codi.15946 34623739
Golas MM, Gunawan B, Cakir M, Cameron S, Enders C, Liersch T, Füzesi L, Sander B. Evolutionary patterns of chromosomal instability and mismatch repair deficiency in proximal and distal colorectal cancer. Colorectal Dis. 2022;24(2):157–76. 10.1111/codi.15946.34623739 10.1111/codi.15946
107. Ghosh D Nandi S Bhattacharjee S Combination therapy to checkmate glioblastoma: clinical challenges and advances Clin Transl Med 2018 7 1 33 10.1186/s40169-018-0211-8 30327965
Ghosh D, Nandi S, Bhattacharjee S. Combination therapy to checkmate glioblastoma: clinical challenges and advances. Clin Transl Med. 2018;7(1):33. 10.1186/s40169-018-0211-8.30327965 10.1186/s40169-018-0211-8
108. Godek KM Venere M Wu Q Mills KD Hickey WF Rich JN Compton DA Chromosomal instability affects the tumorigenicity of glioblastoma tumor-initiating cells Cancer Discov 2016 6 5 532 545 10.1158/2159-8290.CD-15-1154 27001151
Godek KM, Venere M, Wu Q, Mills KD, Hickey WF, Rich JN, Compton DA. Chromosomal instability affects the tumorigenicity of glioblastoma tumor-initiating cells. Cancer Discov. 2016;6(5):532–45. 10.1158/2159-8290.CD-15-1154.27001151 10.1158/2159-8290.CD-15-1154
109. Bakhoum SF Landau DA Chromosomal Instability as a Driver of Tumor Heterogeneity and Evolution Cold Spring Harb Perspect Med 2017 7 6 a029611 10.1101/cshperspect.a029611 28213433
Bakhoum SF, Landau DA. Chromosomal Instability as a Driver of Tumor Heterogeneity and Evolution. Cold Spring Harb Perspect Med. 2017;7(6):a029611. 10.1101/cshperspect.a029611.28213433 10.1101/cshperspect.a029611
